이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

A Study of RSS0343 Tablets in Healthy Participants and in Participants With Mild or Moderate Renal Impairment

2026년 11월 11일 업데이트: Reistone Biopharma Company Limited

A Pharmacokinetic Study of RSS0343 Tablets in Healthy Participants and in Participants With Mild or Moderate Renal Impairment

This study is a single-center, single-dose, open-label study designed to evaluate the pharmacokinetic (PK) profile of RSS0343 tablets in healthy participants and in participants with mild or moderate renal impairment.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

24

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

    • Henan
      • Zhengzhou, Henan, 중국, 450052
        • The First Affiliated Hospital of Zhengzhou University
        • 수석 연구원:
          • Youhong Hu
        • 수석 연구원:
          • Zhanzheng Zhao

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Participants voluntarily sign the informed consent form (ICF), have a full understanding of the purpose and significance of this study, and are willing to comply with the study protocol.
  2. Males or females aged 18 to 65 years (both boundaries inclusive).
  3. Body weight ≥ 50 kg for males and ≥ 45 kg for females; body mass index (BMI) = weight (kg) / height² (m²), with BMI within the range of 19 to 28 kg/m² (both boundaries inclusive).
  4. The absolute value of estimated glomerular filtration rate (eGFR) shall be calculated using the Modification of Diet in Renal Disease (MDRD) equation modified for the Chinese population (for the equation and calculation method). Participants with mild renal impairment: absolute eGFR of 60-89 mL/min; participants with moderate renal impairment: absolute eGFR of 30-59 mL/min (boundary values inclusive); healthy participants: absolute eGFR ≥ 90 mL/min and < 130 mL/min.
  5. Male and female participants of reproductive / childbearing potential and their partners must have no plan for pregnancy or for sperm / oocyte donation within 6 months (female participants) or 3 months (male participants) after the last dose, and must be willing to use highly effective contraceptive measures. Female participants of childbearing potential must have a negative serum pregnancy test prior to the first dose and must not be breastfeeding.
  6. (For participants with renal impairment, the following additional inclusion criteria must also be met) The participant has been diagnosed with chronic (> 3 months) and stable renal injury (no acute exacerbation due to deterioration of renal function within 1 month prior to screening), and medical records or laboratory reports confirming the diagnosis of renal impairment for more than 3 months must be provided.
  7. (Participants with normal renal function) Physical examination, 12-lead electrocardiogram (12-ECG), vital signs, chest imaging, abdominal ultrasonography (color Doppler ultrasound) and laboratory tests at screening and baseline are normal, or abnormal without clinical significance.

Exclusion Criteria:

  1. Those who smoked more than 5 cigarettes per day (or used an equivalent amount of other nicotine-containing products) within 3 months prior to screening, or who plan to use any tobacco products during the study.

  2. Regular alcohol drinkers within 6 months prior to screening (i.e., daily alcohol intake exceeding 15 g for females and 25 g for males [5 g of alcohol is equivalent to 150 mL of beer, 50 mL of wine, or approximately 17 mL of low-alcohol liquor], on more than 2 occasions per week) who are unable to abstain from any alcohol-containing products during the study; or those with a positive alcohol breath test at baseline.

  3. Those with a history of drug abuse, illicit drug use, or drug dependence (as determined by interview/medical history), or a positive urine drug screen at baseline.

  4. Blood donation or blood loss of ≥ 200 mL in total within 1 month prior to dosing, or ≥ 400 mL in total within 3 months prior to dosing; receipt of a blood transfusion within 8 weeks prior to dosing; difficult venipuncture, or a physical condition that cannot tolerate intensive blood collection.

  5. Positive test results for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (anti-HCV), syphilis antibody, or human immunodeficiency virus (HIV) antibody.

  6. Suspected allergy / hypersensitivity to the investigational product or any of its components, or a history of severe allergy to any drug, food, toxin, or other exposure.

  7. Any surgery within 3 months prior to screening, or incomplete recovery from surgery as judged by the investigator, or any surgery planned during the study period through 1 month after the end of the study.

  8. Participants who refuse to abstain from any methylxanthine-containing beverages or foods (e.g., coffee, tea, cola, chocolate) from 48 hours prior to baseline until the end of the study; who refuse to abstain from any grapefruit-containing beverages or foods from 7 days prior to baseline until the end of the study; or who have special dietary requirements and are unable to comply with the standardized diet provided in the study.

  9. Receipt of any live vaccine or live-attenuated vaccine within 1 month prior to screening, or a requirement for vaccination with a live vaccine during study participation (including within 30 days after the last dose of the investigational product).

  10. Those who have participated in any clinical trials involving drugs or medical devices within three months prior to signing the informed consent form (or within five elimination half-lives of the studied drug, whichever is the longer period), excluding those who participated in other clinical trials but were not administered the drug due to screening failure.

    Exclusion criteria for participants with renal dysfunction:

  11. According to the judgment of the researchers, participants with renal dysfunction who are not suitable to participate in the study (such as those who have undergone kidney transplantation, those with urinary incontinence or anuria).

  12. Those who, in the investigator's judgment, have experienced marked fluctuation or rapid deterioration of renal function within 2 weeks prior to dosing.

  13. Those who have received renal replacement therapy (e.g., hemodialysis) within 3 months prior to screening, or who are expected to receive renal replacement therapy during the study.

  14. Those with underlying diseases contributing to chronic kidney disease (e.g., diabetes mellitus, hypertension) that have been poorly controlled within 3 months prior to screening, as judged by the investigator.

  15. Other than the primary renal disease itself, any history of serious disease, or any medical history and/or clinically significant abnormal clinical laboratory findings that, in the investigator's opinion, may affect the study results, including but not limited to a history of diseases of the circulatory, endocrine, nervous or digestive systems, or hematologic, immune, psychiatric or metabolic diseases.

  16. Use of any prescription drugs, over-the-counter (OTC) drugs, Chinese patent medicines or dietary supplements, other than those used for the treatment of renal impairment and other concomitant diseases, within 2 weeks prior to administration of the study drug; or use of strong inhibitors or inducers of CYP3A4 and/or P-glycoprotein (P-gp) within 2 weeks prior to administration of the study drug.

    Exclusion criteria for participants with normal renal function:

  17. Previous severe primary diseases of important organs, including but not limited to gastrointestinal, respiratory, renal, liver, nervous, hematological, endocrine, tumor, immune, mental or cardiovascular and cerebrovascular diseases.

  18. Use of any medication (including prescription drugs, over-the-counter drugs, herbal medicines, Chinese patent medicines, and dietary supplements) within 4 weeks prior to screening, or still within 5 half-lives of a drug at the time of screening (whichever is longer).

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: RSS0343 Tablet Group

Administration of RSS0343 tablet.

RSS0343 tablet, oral.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
The maximum plasma concentration (Cmax)
기간: Day 1 - Day 12.

The PK Parameter.

Day 1 - Day 12.
The area under the blood drug concentration-time curve from Time 0 to the last quantifiable concentration time (AUC0-t)
기간: Day 1 - Day 12.

The PK Parameter.

Day 1 - Day 12.
The area under the blood drug concentration-time curve from Time 0 to the extrapolated infinite time (AUC0-inf)
기간: Day 1 - Day 12.

The PK Parameter.

Day 1 - Day 12.

2차 결과 측정

결과 측정
측정값 설명
기간
Time to maximum plasma concentration (Tmax)
기간: Day 1 - Day 12.

The PK Parameter.

Day 1 - Day 12.
Terminal half-life (t1/2)
기간: Day 1 - Day 12.

The PK Parameter.

Day 1 - Day 12.
Apparent clearance (CL/F)
기간: Day 1 - Day 12.

The PK Parameter.

Day 1 - Day 12.
Apparent volume of distribution (Vz/F)
기간: Day 1 - Day 12.

The PK Parameter.

Day 1 - Day 12.
Cumulative amount of drug excreted unchanged in urine (Ae)
기간: Day 1 - Day 12.

The PK Parameter.

Day 1 - Day 12.
Fraction of the administered dose excreted unchanged in urine (Fe)
기간: Day 1 - Day 12.

The PK Parameter.

Day 1 - Day 12.
Renal clearance (CLr)
기간: Day 1 - Day 12.

The PK Parameter.

Day 1 - Day 12.
Plasma protein binding (PPB)
기간: Day 1 - Day 12.

The PK Parameter.

Day 1 - Day 12.
Incidence and severity of adverse events (AEs)
기간: Day 1 - Day 12.

Safety Parameter.

Day 1 - Day 12.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 11월 1일

기본 완료 (추정된)

2027년 2월 1일

연구 완료 (추정된)

2027년 4월 1일

연구 등록 날짜

최초 제출

2026년 11월 11일

QC 기준을 충족하는 최초 제출

2026년 11월 11일

처음 게시됨 (실제)

2026년 11월 17일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 17일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 11일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • RSS0343-105

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .